An Open Label, Prospective Study of the Analgesic Efficacy of Oral Xartemis Compared to Generic Oxycodone/APAP( Acetaminophen) in the Treatment of Moderate to Severe Post Operative Pain.

NCT ID: NCT02101476

Last Updated: 2018-04-09

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE4
• Total Enrollment: 114 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2014-05-31
• Study Completion Date: 2014-10-31

Brief Summary

The purpose of this study is to compare the analgesic efficacy of Xartemis 15mg/650mg by mouth every 12 hours for the management of acute moderate to severe post operative pain to generic Oxycodone/APAP(acetaminophen) (Percocet) 10mg/650mg by mouth every 6 hours.

Conditions

Post Operative Pain

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Percocet

Oxycodone/APAP (acetaminophen)

Group Type: ACTIVE_COMPARATOR

Percocet

Intervention Type: DRUG

10mg/650mg

Xartemis

Group Type: ACTIVE_COMPARATOR

Xartemis

Intervention Type: DRUG

15mg/650mg

Interventions

Percocet

10mg/650mg

Intervention Type: DRUG

Xartemis

15mg/650mg

Intervention Type: DRUG

Other Intervention Names

Oxycodone/APAP(acetaminophen)

Eligibility Criteria

Inclusion Criteria

• Patients who provide written informed consent prior to enrollment
• Male or female and 18 years of age or older.
• Patients who are scheduled to undergo elective general surgery including, but not limited to the following surgical types:

• Abdominal surgery
• Orthopedic surgery
• Spine surgery
• Genitourinary surgery
• Patient classified as American Society of Anesthesiologists (ASA class I-III).
• Female subjects are eligible only if all of the following apply:

• Not pregnant (subjects of child bearing potential must have a negative beta human chorionic gonadotropin (β-hCG) pregnancy test before surgery);
• Not lactating;
• Not planning to become pregnant within the duration of the study;
• Patients who are expected to have acute pain requiring oral opioid analgesics for at least 48 hours during the post operative period (either inpatient or outpatient).
• Patient must report a categorical pain rating of moderate to severe on a scale of none, mild, moderate, or severe prior to randomization.
• Patients who are willing and capable of understanding and cooperating with the requirements of the study.
• Patients able to understand and communicate in English.

Exclusion Criteria

• Patients with a medical condition that, in the Investigator's opinion, could adversely impact the patient's participation, safety, or conduct of the study such as but not limited to a history of severe renal or hepatic impairment, severe active hepatic disease, or any other clinically significant medical condition that may preclude safe study participation
• Patients who have a known severe allergy or hypersensitivity to opioid analgesics, anesthetics, APAP (acetaminophen.)
• Patients who have a history of intolerance to short term opioid use.
• Patients who have abused any prescription medication or alcohol within two years before the start of the study.
• Patients who require an additional scheduled surgical procedure within 48 hours of the surgery.
• Patients who have a history of seizures, or are currently taking anticonvulsants.
• Patients who have dysphagia and/or cannot swallow study medication whole.
• Patient who is unable to adequately communicate with study staff, properly give informed consent, or otherwise comply with study procedures.
• Patient who has participated in another clinical trial of an investigational drug or device within 30 days of screening visit or is schedule to receive an investigational product while participating in the study.

• Patients who are not awake, not breathing spontaneously, or have a respiratory insufficiency.
• Patients who are vomiting and not responsive to standard treatment
• Patients not able to answer questions and follow commands.
• Patients who have surgical complications that could compromise safety of the subject or confound the results of the study.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Mallinckrodt

INDUSTRY

Sponsor Role: collaborator

Lotus Clinical Research, LLC

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Neil Singla, MD

Role: PRINCIPAL_INVESTIGATOR

Lotus Clinical Research, LLC

Locations

Lotus Clinical Resarch,LLC

Pasadena, California, United States

Countries

United States

Other Identifiers

LCR-MNK-01C

Identifier Type: -

Identifier Source: org_study_id